---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105839"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:45:47.727669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP

## Summary
- Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.
- Cash and cash equivalents $90.4M at June 30, 2025, down from $101.6M at March 31, 2025.
- Appointed Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development; also formed Clinical Advisory Board with four retinal specialists.
- Granted U.S. Patent No. 12,297,278 covering SWAP multi-specific Wnt surrogate technology; IND submission for SZN-8141 targeted for 2026.
- R&D expenses $6.0M (up from $5.3M) and G&A $4.0M (up from $3.7M); research service revenue from related party $1.0M.

## SEC filing metadata
- accession: 0000950170-25-105839
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/0000950170-25-105839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/srzn-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105839
- JSON: https://secwatch.observer/filing/0000950170-25-105839.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.